THERAVECTYS
Theravectys is a development-stage biotechnology company with a novel vaccine platform that can be applied to the treatment and prevention of a broad range of infectious diseases, cancers, and other diseases and conditions. Their first clinical studies will be in HIV/AIDS, using their lead product, a therapeutic vaccine, which has shown promising efficacy and safety in non-human primates.
THERAVECTYS
Industry:
Biopharma Biotechnology Health Care
Founded:
2005-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.theravectys.site
Total Employee:
1+
Status:
Active
Contact:
33 1 44 38 93 13
Total Funding:
40.58 M EUR
Technology used in webpage:
Domain Not Resolving Euro Person Schema Gravatar Profiles UNPKG Leaflet OpenStreetMap
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Vaxcyte
Vaxcyte focuses on developing vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.
Current Advisors List
Current Employees Featured
Founder
Investors List
Bpifrance
Bpifrance investment in Grant - Theravectys
Tethys BioScience
Tethys BioScience investment in Series D - Theravectys
Guy PAILLAUD
Guy PAILLAUD investment in Series C - Theravectys
Richard HENNESSY
Richard HENNESSY investment in Series C - Theravectys
Philippe ODDO
Philippe ODDO investment in Series C - Theravectys
John PIETERS
John PIETERS investment in Series C - Theravectys
More informations about "Theravectys"
ABOUT US - TheraVectys : Immunize - Treat - Cure
TheraVectys is pioneering the application of novel lentiviral vector technology to address most of unmet and critical medical needs. By creating the only Joint-Laboratory between a private company and the Institut Pasteur in Paris, …See details»
Theravectys - Crunchbase Company Profile & Funding
Theravectys is a development-stage biotechnology company with a novel vaccine platform that can be applied to the treatment and prevention of a broad range of infectious diseases, …See details»
THERAVECTYS Company Overview, Contact Details & Competitors …
Feb 8, 2021 Learn more about THERAVECTYS's company details, contact information, competitors, and more. Find accurate contact data easily with LeadIQ. Book a demo today. ...See details»
PIPELINE - TheraVectys : Immunize - Treat - Cure
In June 2017, TheraVectys and Pasteur Institute created a Joint-Laboratory to focus the company on its core business, pre-clinical research and reinforce collaboration with the Institut Pasteur, ensuring the continuous follow-up of …See details»
THERAVECTYS - LinkedIn
THERAVECTYS | 3,297 followers on LinkedIn. Based in Paris and in the USA, TheraVectys is an immunotherapy company spun off from the Institut Pasteur created in 2005 by Dr. Pierre Charneau.See details»
Theravectys Company Profile 2024: Valuation, Funding …
Website www.theravectys.com. Ownership Status. Privately Held (backing) Financing Status. Venture Capital-Backed. Corporate Office. 25-28 Rue du Docteur Roux; 75015 Paris; FranceSee details»
OUR MISSION - TheraVectys : Immunize - Treat - Cure
In June 2017, TheraVectys and the Institut Pasteur formed a Joint-Laboratory to build a solid portfolio of potential candidates for clinical development. To support the development of our …See details»
Theravectys - Contacts, Employees, Board Members, Advisors
Organization. Theravectys . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. ... Theravectys has 2 board members and …See details»
Theravectys Company Profile - Office Locations, Competitors
Theravectys has 5 employees across 2 locations and $31.68 m in total funding,. See insights on Theravectys including office locations, competitors, revenue, financials, executives, …See details»
Theravectys – COBIOE
Website* Telephone* Email* Address. Company address. Postal code* City* Region. Country* Networks. Linkedin. Twitter. RSS. Sign up. My company is already referenced. Select my …See details»
Theravectys announces $20M funding round
Theravectys announced today it has secured $20M in funding, which the company will use to commence in-human testing of its lentiviral-vector based vaccines against SARS-CoV2, HPV …See details»
Theravectys - Funding, Financials, Valuation & Investors
Theravectys develops a platform for the prevention and treatment of cancers and other infectious diseases and conditions. Search Crunchbase. Start Free Trial . ... How much funding has this …See details»
Theravectys - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Nov 17, 2024 Theravectys uses 14 technology products and services including HTML5, Comodo PositiveSSL Certificates, and Google Maps API, according to G2 Stack. Theravectys is …See details»
Theravectys: an Orphan Drug Designation for Its ... - Labiotech.eu
Feb 22, 2015 THERAVECTYS, a fully-integrated discovery and clinical development biotechnology company focusing on the development of therapeutic vaccines and immunotherapy, announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to its therapeutic vaccine candidate for the treatment of Adult T-cell …See details»
Theravectys CEO and Key Executive Team | Craft.co
Theravectys's Chief Scientific Officer is Pierre Charneau. Other executives include Jean Chalopin, Chairman; Ye Tian, Chief Executive Officer. See the full leadership team at Craft.See details»
Lentiviral-based anti-HIV therapeutic vaccine: design, preclinical ...
May 23, 2014 THERAVECTYS’ anti-HIV vaccine treatment is assessed at three doses and safety, tolerability and immunogenicity compared to a placebo group. Furthermore, vaccine efficiency is be evaluated by the interruption of the HAART treatment in all patients, including placebo. Final results are expected by 2014 with intermediary analysis in April 2014.See details»
TECHNOLOGY - TheraVectys : Immunize - Treat - Cure
TheraVectys’ proprietary lentiviral vector technology is continuously optimized to deliver unrivalled capacity to induce strong, efficient and long lasting cellular immune responses and humoral …See details»
Human Papillomavirus (HPV)-induced Cancers: First Patient
Oct 4, 2024 TheraVectys, a biotechnology company that designs and develops lentiviral vector-based vaccines and immunotherapies against infectious agents and cancers, announces that …See details»
Research programme: oncology vaccines - Theravectys
THERAVECTYS, a development-stage biotechnology company based in France, is developing vaccines for the treatment of cancer including adult T-cell Research programme: oncology …See details»